Steroid response in refractory asthmatics

Korean Journal of Internal Medicine

Volumn 27, Issue 2, 2012, Pages 143-148

  Jang, An Soo ^a  

^a Soonchunhyang University   (South Korea)

Author keywords

Asthma; Drug resistance; Glucocorticoids

Indexed keywords

FLUTICASONE PROPIONATE; GLUCOCORTICOID;

ASTHMA; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE CONTROL; DISEASE SEVERITY; DRUG MECHANISM; DRUG RESPONSE; HEALTH CARE COST; HUMAN; PATHOPHYSIOLOGY; REFRACTORY ASTHMA; REVIEW; RISK FACTOR;

ADMINISTRATION, INHALATION; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; DRUG RESISTANCE; GLUCOCORTICOIDS; HUMANS; LUNG; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84862836197     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2012.27.2.143     Document Type: Review

References (41)

1. The Korean Academy of Asthma, Allergy and Clinical Immunology. Treatment 2007 Korea adult asthma treatment guideline [Internet]. Seoul (KR): The Korean Academy of Asthma, Allergy and Clinical Immunology, c2005 [cited 2012 Mar 20]. Available from: http://www.allergy.or.kr.
2. The Korean Academy of Asthma, Allergy and Clinical Immunology. Treatment guideline of asthma in Korea [Internet]. Seoul (KR): The Korean Academy of Asthma, Allergy and Clinical Immunology, c2005 [cited 2012 Mar 20]. Available from: http://www.allergy.or.kr.
3. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma (EPR-3) [Internet]. Bethesda (MD): National Heart, Lung, and Blood Institute, 2007 [cited 2012 Mar 20]. Available from: http://www.nhlbi.nih.gov/guidelines/asthma.
4. James AL, Maxwell PS, Pearce-Pinto G, Elliot JG, Carroll NG. The relationship of reticular basement membrane thickness to airway wall remodeling in asthma. Am J Respir Crit Care Med 2002;166(12 Pt 1):1590-1595.
5. Chetta A, Foresi A, Del Donno M, Bertorelli G, Pesci A, Olivieri D. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 1997;111:852-857.
6. Reed CE. The natural history of asthma in adults: the problem of irreversibility. J Allergy Clin Immunol 1999;103:539-547.
7. Ten Hacken NH, Postma DS, Timens W. Airway remodeling and long-term decline in lung function in asthma. Curr Opin Pulm Med 2003;9:9-14.
8. Wenzel S. Mechanisms of severe asthma. Clin Exp Allergy 2003;33:1622-1628.
9. Wenzel S. Severe/fatal asthma. Chest 2003;123(3 Suppl):405S- 410S.
10. Wenzel S. Severe asthma: epidemiology, pathophysiology and treatment. Mt Sinai J Med 2003;70:185-190.
11. Heaney LG, Robinson DS. Severe asthma treatment: need for characterizing patients. Lancet 2005;365:974-976.
12. Heaney LG, Conway E, Kelly C, et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax 2003;58:561-566.
13. Stirling RG, Chung KF. Severe asthma: definition and mechanisms. Allergy 2001;56:825-840.
14. Afzal M, Tharratt RS. Mechanical ventilation in severe asthma. Clin Rev Allergy Immunol 2001;20:385-397.
15. Robinson DS, Campbell DA, Durham SR, et al. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003;22:478-483.
16. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions: American Thoracic Society. Am J Respir Crit Care Med 2000;162:2341-2351.
17. Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J 1998;12:1209-1218.
18. Chung KF, Godard P, Adelroth E, et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J 1999;13:1198-1208.
19. Chu HW, Trudeau JB, Balzar S, Wenzel SE. Peripheral blood and airway tissue expression of transforming growth factor beta by neutrophils in asthmatic subjects and normal control subjects. J Allergy Clin Immunol 2000;106:1115-1123.
20. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003;22:470-477.
21. Tillie-Leblond I, Gosset P, Tonnel AB. Inflammatory events in severe acute asthma. Allergy 2005;60:23-29.
22. National Asthma Education and Prevention Program. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics-2002. J Allergy Clin Immunol 2002;110(5 Suppl):S141-S219.
23. Sandford AJ, Chagani T, Zhu S, et al. Polymorphisms in the IL4, IL4RA, and FCERIB genes and asthma severity. J Allergy Clin Immunol 2000;106(1 Pt 1):135-140.
24. Spiteri MA, Bianco A, Strange RC, Fryer AA. Polymorphisms at the glutathione Stransferase, GSTP1 locus: a novel mechanism for susceptibility and development of atopic airway inflammation. Allergy 2000;55 Suppl 61:15-20.
25. Chu HW, Balzar S, Westcott JY, et al. Expression and activation of 15-lipoxygenase pathway in severe asthma: relation- ship to eosinophilic phenotype and collagen deposition. Clin Exp Allergy 2002;32:1558-1565.
26. Szalai C, Kozma GT, Nagy A, et al. Polymorphism in the gene regulatory region of MCP-1 is associated with asthma susceptibility and severity. J Allergy Clin Immunol 2001;108:375-381.
27. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflam- matory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001-1008.
28. Jang AS, Lee JH, Park SW, et al. Factors influencing the responsiveness to inhaled glucocorticoids of patients with moderate-to-severe asthma. Chest 2005;128:1140-1145.
29. Vignola AM, Mirabella F, Costanzo G, et al. Airway remodeling in asthma. Chest 2003;123(3 Suppl):417S-422S.
30. Jeffery PK, Wardlaw AJ, Nelson FC, Collins JV, Kay AB. Bronchial biopsies in asthma: an ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis 1989;140:1745-1753.
31. Takeyama K, Fahy JV, Nadel JA. Relationship of epidermal growth factor receptors to goblet cell production in human bronchi. Am J Respir Crit Care Med 2001;163:511-516.
32. Carroll NG, Mutavdzic S, James AL. Distribution and degranulation of airway mast cells in normal and asthmatic subjects. Eur Respir J 2002;19:879-885.
33. Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol 2006;533:2-14.
34. Leung DY, Hamid Q, Vottero A, et al. Association of gluco-corticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 1997;186:1567-1574.
35. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 2005;172:149-160.
36. Barnes PJ. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004;1:264-268.
37. Chung KF. Individual cytokines contributing to asthma pathophysiology: valid targets for asthma therapy? Curr Opin Investig Drugs 2003;4:1320-1326.
38. Barnes PJ. New drugs for asthma. Nat Rev Drug Discov 2004;3:831-844.
39. Hedley ML. Gene therapy of chronic inflammatory disease. Adv Drug Deliv Rev 2000;44:195-207.
40. Bryan SA, Leckie MJ, Hansel TT, Barnes PJ. Novel therapy for asthma. Expert Opin Investig Drugs 2000;9:25-42.
41. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008;372:1073-1087.